Co-investment Platform with Reduced Risk and Unmatched Liquidity
Focus and Guidelines
We are well-positioned to achieve venture returns with reduced risk and higher liquidity by investing in late-stage venture-backed healthcare companies while also capitalizing on China’s robust healthcare demand for the U.S’s advanced technology to strategically create value for our portfolio companies. Our structure gives our investors the option to participate at their sole discretion in each fully underwritten deal led by a prestigious Venture Capital firm, providing unmatched flexibility and transparency.
Profitability & Cash Flow
EBITDA > US$ 2 million
Capital raised should fund operations for at least 3 years
Global investments with a focus on product/service commercialization in China
Target Company Size
Revenue > US$20 million
Annual top line growth of > 40%
Diagnostics & Tools
Medical Devices & Supplies
Active Involvement in Deal Lifecycle
Comprehensive and detail-oriented value-creation strategy ensures our participation in the full private equity investment process - from deal-sourcing to exit strategy.
Abundant connections and resources in the United States healthcare and finance industries strongly support investment deal-sourcing.
Deep experience in cross-border commercialization and operational management help to create value for portfolio companies.
Vast network of medical and financial institutions will provide a multi-faceted exit strategy ranging from traditional IPO to strategic sales.
152 W57th Street, Carnegie Hall Tower, 49th Floor, New York